positive opinion recommending approval of Nektar Therapeutics ' (NASDAQ: NKTR ) Moventig ( naloxegol ) for the treatment ..... gastrointestinal tract. The drug candidate is based on Nektar Therapeutics ' ( NKTR ) oral small molecule polymer conjugate technology
treatment of opioid-induced constipation (OIC). Salix ( SLXP +5% ) successfully appealed the FDA's CRL for the indication in July. ( PGNX +0.6% )( NKTR +1.8% )( AZN -4% )( CBST +0.6% )( SGYP +3.1% ) Post your comment!
Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .
The FDA approves Nektar Therapeutics ' ( NKTR -0.1% ) Movantik ( naloxegol ) for the treatment of patients with opioid-induced constipation who take opioids for the management
By Stephen Simpson, CFA : Investors who like Nektar Therapeutics (NASDAQ: NKTR ) or Alkermes (NASDAQ: ALKS ) may want to take a look at Britain's Vectura Group plc (OTC: VEGPF ) (VEC.L). Although
By Scrying Biotech : Chronic pain suppression in the U.S. is a $13B market annually whose landscape is constantly changing based upon the unintended consequences of drug addiction. The most popular of these opiates is Purdue's OxyContin, ranked 18th in total U.S. sales last year at $2.46B. Sales of
develop broad pipelines have fared a little better. Nektar Therapeutics (NASDAQ: NKTR ) belongs on that list, as the company continues ..... Nektar's PEGylated naloxol (also known as NKTR -118) has less than a month to go before it should
By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...
(Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.
We are dropping coverage of Nektar Therapeutics NKTR to focus our resources elsewhere.